Tinnitus

In this edition, FDA clears lab blood test for evaluating concussion, marriage linked to lower risk for dementia, FDA approves nasal spray for migraine in adults and more.

The FDA has granted de novo approval to Neuromod Devices’ Lenire, a noninvasive device for the treatment of tinnitus and the first of its kind to receive approval in the United States, according to a company press release.

Most patients considered using and learning more about cannabis as a treatment to relieve their tinnitus and related symptoms, a recent study found.

Residential exposure to traffic noise was linked to an increased risk for tinnitus, a finding that researchers said adds to the evidence of traffic noise as a growing health burden.

In this edition, leisure activities may lower risk for Alzheimer's disease and dementia; most common long COVID symptoms include fatigue and headache; ‘life-changing’ app-based digital therapeutic for tinnitus and more.

In this edition, light stimulation may help delay Alzheimer’s progression; sleep EEGs may predict future disease and mortality; updated data on the prevalence of tinnitus and more.

Patients with tinnitus who used a digital therapeutic system that combines goal-based counseling with personalized sound therapy showed clinically significant improvement after 12 weeks, researchers reported in Frontiers in Neurology.

Tinnitus affects more than 740 million adults worldwide and is viewed as a major problem by over 120 million, highlighting the need for improved research and patient care, according to a systematic review in JAMA Neurology.

More than half of adults who underwent chemotherapy for breast, gastrointestinal, gynecologic or lung cancer had confirmed hearing loss, and more than 35% had tinnitus, according to data published in BMJ Supportive & Palliative Care.

Tinnitus was significantly associated with pre-existing primary open-angle glaucoma, researchers reported in the Journal of Glaucoma.